Micro- and nanoscale technologies are emerging as powerful enabling tools for tissue engineering and drug discovery. In tissue engineering, micro- and nanotechnologies can be used to fabricate biomimetic scaffolds with increased complexity and vascularization.
The whole 16 pages article is available for download here.
Arthritis, an inflammation of the joints, is usually a chronic disease that results from dysregulation of pro-inflammatory cytokines (e.g. tumour necrosis factor and interleukin-1b) and pro-inflammatory enzymes that mediate the production of prostaglandins (e.g. cyclooxygenase-2) and leukotrienes
(e.g. lipooxygenase), together with the expression of adhesion molecules and matrix metalloproteinases, and hyperproliferation of synovial fibroblasts. All of these factors are regulated by the activation of the transcription factor nuclear factor-kB. Thus, agents that suppress the expression of tumour necrosis factor-a, interleukin-1b, cyclooxygenase-2, lipooxygenase, matrix metalloproteinases or adhesion molecules, or suppress the activation of NF-kB, all have potential for the treatment of arthritis.
The whole 8 pages article is available for download here.
Nanoparticles (NP) are defined as particles with a diameter smaller than 100 nm, are increasingly used in different applications, including drug carrier systems and to pass organ barriers such as the blood-brain barrier. Because of their unique properties Nanocrystals (quantum dots) and other nanoparticles (gold colloids, nanobars, dendrimers and nanoshells) have been receiving a lot of attention for potential use in Therapeutics, Bioengineering and therapeutics drug discovery.
The whole 17 pages article is available for download here.
SMi Group Reports: (2016.11.16, London, UK): Over 90 senior leaders in parallel trade will meet in London in February 2017 to discuss upcoming trends and share best practices.
With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? SMi’s Parallel Trade conference will be returning to London next February 6th-7th, for its 11th year, to discuss short term and long term concerns of pharma manufacturers, regulators and parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges.
Dubai, 16 August 2015:
The shift from product to patient-centered practice in pharmacy is said to be a leading trend in the globe nowadays. The GCC region, believed by some experts to witness rapid developments in its pharmacy practice and education, is among those who are moving towards this trend.
Dr. Lamia Yahya, Clinical Pharmacist at Corniche Hospital in the UAE, believes that the pharmacy practice in the region is booming and is an actively growing profession. "It had moved away from the classic role of just ‘handing in' the medication to the patient, to more orientation towards patient care," she adds. However, some expert suggests that the entire region should place a great emphasis to effectively further advance the profession. An expert from Qatar, Dr. Ahmed Nadir Kheir, Associate Professor and Continuing Professional Pharmacy Development (CPPD) Coordinator for Qatar University, shares that one of the most important factors and tools of change is the advancement in pharmacy education and the emergence of accreditation initiatives, which target quality in health care.
